In this Product Explainer, Consultant Paediatric Immunologist and Paediatrician Prof Peter Richmond provides an update on the 20vPnC pneumococcal conjugate vaccine including availability and eligibility (4 mins).
In this Product Explainer, Infectious Disease Physician and Clinical Microbiologist Prof Paul Griffin provides an update on the intranasal flu vaccine now available and provides a detailed demonstration of how to use the device (8 mins).
In this short video, Prof Paul Griffin provides an update on respiratory viruses, emphasising the critical need to increase vaccination uptake, particularly for COVID-19, Influenza and Respiratory syncytial virus (RSV), and the need for healthcare professionals to actively promote and facilitate co-administration.
In this Product Explainer, Infectious Disease Physician and Microbiologist Prof Paul Griffin explains the role of a recombinant respiratory syncytial virus pre-fusion F protein vaccine for prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).
In this Product Explainer Geriatrician A/Prof Michael Woodward AM explains an adjuvanted vaccine indicated for the active immunisation of individuals 60 years and older for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).1
All WA babies under eight months old, as well as those aged eight to 19 months at increased risk of severe RSV infection, will be eligible for monoclonal antibodies.